Chemotherapy for advanced head and neck cancer with the combination Adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen

E. T. Creagan, T. R. Fleming, J. H. Edmonson, J. N. Ingle, J. E. Woods

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m 2, day 1; cyclophosphamide, 400 mg/m 2, day 3; and cis-diamminedichloroplatinum, 20 mg/m 2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0/12 squamous cell carcinomas; 1/2 adenocarcinomas) and a median survival of five months for all patients was accompanied by considerable gastrointestinal toxicity. These results strikingly diverge from a prior study that achieved a 64% (16/25) regression rate using comparable doses of each agent but was administered by rapid infusion on one day each month (CAP-1). Admittedly, the relatively impaired performance scores of the CAP-3 participants may have had some impact on these discouraging results. On the other hand, the maximum therapeutic efficacy of the combination Adriamycin, cyclophosphamide, and cis-platinum may well depend upon subtle interactions of cell cycle kinetics and dosage and schedule of each agent.

Original languageEnglish (US)
Pages (from-to)2549-2551
Number of pages3
JournalCancer
Volume47
Issue number11
DOIs
StatePublished - 1981

Fingerprint

Head and Neck Neoplasms
Doxorubicin
Cyclophosphamide
Cisplatin
Drug Therapy
Pharmaceutical Preparations
Squamous Cell Carcinoma
Appointments and Schedules
Cell Cycle
Adenocarcinoma
Neck
Head
Carcinoma
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy for advanced head and neck cancer with the combination Adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II) : Preliminary assessment of a one-day vs. three-day drug regimen. / Creagan, E. T.; Fleming, T. R.; Edmonson, J. H.; Ingle, J. N.; Woods, J. E.

In: Cancer, Vol. 47, No. 11, 1981, p. 2549-2551.

Research output: Contribution to journalArticle

@article{8c5cfb40c4cf4b1aa3aee9a47b183263,
title = "Chemotherapy for advanced head and neck cancer with the combination Adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen",
abstract = "Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m 2, day 1; cyclophosphamide, 400 mg/m 2, day 3; and cis-diamminedichloroplatinum, 20 mg/m 2/1 hour, days 1-3 (CAP-3). A regression rate of only 7{\%} (0/12 squamous cell carcinomas; 1/2 adenocarcinomas) and a median survival of five months for all patients was accompanied by considerable gastrointestinal toxicity. These results strikingly diverge from a prior study that achieved a 64{\%} (16/25) regression rate using comparable doses of each agent but was administered by rapid infusion on one day each month (CAP-1). Admittedly, the relatively impaired performance scores of the CAP-3 participants may have had some impact on these discouraging results. On the other hand, the maximum therapeutic efficacy of the combination Adriamycin, cyclophosphamide, and cis-platinum may well depend upon subtle interactions of cell cycle kinetics and dosage and schedule of each agent.",
author = "Creagan, {E. T.} and Fleming, {T. R.} and Edmonson, {J. H.} and Ingle, {J. N.} and Woods, {J. E.}",
year = "1981",
doi = "10.1002/1097-0142(19810601)47:11<2549::AID-CNCR2820471105>3.0.CO;2-H",
language = "English (US)",
volume = "47",
pages = "2549--2551",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Chemotherapy for advanced head and neck cancer with the combination Adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II)

T2 - Preliminary assessment of a one-day vs. three-day drug regimen

AU - Creagan, E. T.

AU - Fleming, T. R.

AU - Edmonson, J. H.

AU - Ingle, J. N.

AU - Woods, J. E.

PY - 1981

Y1 - 1981

N2 - Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m 2, day 1; cyclophosphamide, 400 mg/m 2, day 3; and cis-diamminedichloroplatinum, 20 mg/m 2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0/12 squamous cell carcinomas; 1/2 adenocarcinomas) and a median survival of five months for all patients was accompanied by considerable gastrointestinal toxicity. These results strikingly diverge from a prior study that achieved a 64% (16/25) regression rate using comparable doses of each agent but was administered by rapid infusion on one day each month (CAP-1). Admittedly, the relatively impaired performance scores of the CAP-3 participants may have had some impact on these discouraging results. On the other hand, the maximum therapeutic efficacy of the combination Adriamycin, cyclophosphamide, and cis-platinum may well depend upon subtle interactions of cell cycle kinetics and dosage and schedule of each agent.

AB - Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m 2, day 1; cyclophosphamide, 400 mg/m 2, day 3; and cis-diamminedichloroplatinum, 20 mg/m 2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0/12 squamous cell carcinomas; 1/2 adenocarcinomas) and a median survival of five months for all patients was accompanied by considerable gastrointestinal toxicity. These results strikingly diverge from a prior study that achieved a 64% (16/25) regression rate using comparable doses of each agent but was administered by rapid infusion on one day each month (CAP-1). Admittedly, the relatively impaired performance scores of the CAP-3 participants may have had some impact on these discouraging results. On the other hand, the maximum therapeutic efficacy of the combination Adriamycin, cyclophosphamide, and cis-platinum may well depend upon subtle interactions of cell cycle kinetics and dosage and schedule of each agent.

UR - http://www.scopus.com/inward/record.url?scp=0019465189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019465189&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19810601)47:11<2549::AID-CNCR2820471105>3.0.CO;2-H

DO - 10.1002/1097-0142(19810601)47:11<2549::AID-CNCR2820471105>3.0.CO;2-H

M3 - Article

C2 - 7196281

AN - SCOPUS:0019465189

VL - 47

SP - 2549

EP - 2551

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -